中/EN: 中文繁體 English

Investor Relations
IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
Corporate

Press Releases

2026

Please select

MAR
25

Triple Agonist UBT251 Showed a Mean HbA_1c Reduction of Up to 2.16% after 24 Weeks in Phase 2 Trial in Chinese Patients with Type 2 Diabetes

MAR
24

The United Laboratories International Holdings Limited Announces 2025 Annual Results, Achieves Significant Progress in Innovative Drug R&D, Out-licensing and Global Expansion, Profit Attributable to Owners of the Company Reaches RMB2,085.9 Million, Declares Final Dividend of RMB26 Cents per Share, with a Full-year Payout Ratio of 38%

FEB
24

Triple Agonist UBT251 Delivers up to 19.7% Mean Weight Loss after 24 Weeks in Phase 2 Trial in China